Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief People Officer | October 01, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date October 01, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 220,867 |
Ending reported balance
After 2026-10-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 8,038 · Balance 228,905 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Row 2 · 2026-10-01 · Exercise / conversion · Acquired 9,377 · Balance 238,282 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Row 3 · 2026-10-01 · Exercise / conversion · Acquired 9,377 · Balance 247,659 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Row 4 · 2026-10-01 · Sale · Disposed 8,094 · Balance 239,565 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 5 · 2026-10-01 · Sale · Disposed 18,698 · Balance 220,867 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.46 · Expires 2033-03-06 | Direct | 16,075 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 8,038 · Balance 16,075 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F4: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2034-03-04 | Direct | 56,259 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,377 · Balance 56,259 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.12 · Expires 2035-03-04 | Direct | 93,765 |
Reported balance
After 2026-10-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-01 · Exercise / conversion · Disposed 9,377 · Balance 93,765 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F6: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy You Jin Lee (spouse) | 2,500 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F5: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F6: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 6, 2026 00:12 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 9,377 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001780660-26-000024 · form4.xml · derivative · entry 9 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,765 Underlying: Common Stock · 9,377 shares Expires 2035-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:12 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 9,377 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780660-26-000024 · form4.xml · derivative · entry 8 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,259 Underlying: Common Stock · 9,377 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:12 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 8,038 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780660-26-000024 · form4.xml · derivative · entry 7 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,075 Underlying: Common Stock · 8,038 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:12 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 18,698 | $28.61 | $534,949.78 |
DisclosureSEC source: 0001780660-26-000024 · form4.xml · nonDerivative · entry 5 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,867 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:12 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 8,094 | $27.52 | $222,746.88 |
DisclosureSEC source: 0001780660-26-000024 · form4.xml · nonDerivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,565 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:12 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 9,377 | $8.12 | $76,141.24 |
DisclosureSEC source: 0001780660-26-000024 · form4.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:12 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 9,377 | $3.99 | $37,414.23 |
DisclosureSEC source: 0001780660-26-000024 · form4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:12 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 8,038 | $8.46 | $68,001.48 |
DisclosureSEC source: 0001780660-26-000024 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 228,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 23:23 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 22,711 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780660-26-000019 · form4.xml · derivative · entry 8 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,511 Underlying: Common Stock · 22,711 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 23:23 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 23,677 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780660-26-000019 · form4.xml · derivative · entry 7 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,246 Underlying: Common Stock · 23,677 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 23:23 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 59,374 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001780660-26-000019 · form4.xml · derivative · entry 6 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,374 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 23:23 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 105,762 | $22.59 | $2,389,163.58 |
DisclosureSEC source: 0001780660-26-000019 · form4.xml · nonDerivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,713 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 23:23 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 22,711 | $8.46 | $192,135.06 |
DisclosureSEC source: 0001780660-26-000019 · form4.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 23:23 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 23,677 | $12.14 | $287,438.78 |
DisclosureSEC source: 0001780660-26-000019 · form4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 23:23 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 59,374 | $7.80 | $463,117.20 |
DisclosureSEC source: 0001780660-26-000019 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 290,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 12,637 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · derivative · entry 20 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,222 Underlying: Common Stock · 12,637 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 12,600 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · derivative · entry 19 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,923 Underlying: Common Stock · 12,600 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 12,626 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · derivative · entry 18 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,374 Underlying: Common Stock · 12,626 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 44,838 | $22.59 | $1,012,890.42 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 11 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,713 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.79, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 12,637 | $8.46 | $106,909.02 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 10 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 12,600 | $12.14 | $152,964.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 9 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 12,626 | $7.80 | $98,482.80 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 8 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 250,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,064 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · derivative · entry 17 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,584 Underlying: Common Stock · 14,064 shares Expires 2035-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F8 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 4,688 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · derivative · entry 16 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,265 Underlying: Common Stock · 4,688 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F7 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 12,206 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · derivative · entry 15 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,859 Underlying: Common Stock · 12,206 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 3,300 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · derivative · entry 14 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,523 Underlying: Common Stock · 3,300 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · derivative · entry 13 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 3,500 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 42,261 | $22.50 | $950,872.50 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 7 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,688 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 8,743 | $22.18 | $193,919.74 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 6 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 279,949 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.48 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,064 | $8.12 | $114,199.68 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 5 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 288,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 4,688 | $3.99 | $18,705.12 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 12,206 | $8.46 | $103,262.76 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,300 | $12.14 | $40,062.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 257,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001780660-26-000017 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 254,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 9,376 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001780660-26-000015 · form4.xml · derivative · entry 10 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,648 Underlying: Common Stock · 9,376 shares Expires 2035-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 2,344 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780660-26-000015 · form4.xml · derivative · entry 9 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,953 Underlying: Common Stock · 2,344 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 2,009 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780660-26-000015 · form4.xml · derivative · entry 8 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,065 Underlying: Common Stock · 2,009 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 5,792 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780660-26-000015 · form4.xml · derivative · entry 7 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,823 Underlying: Common Stock · 5,792 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 39,741 | $17.49 | $695,070.09 |
DisclosureSEC source: 0001780660-26-000015 · form4.xml · nonDerivative · entry 5 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 250,934 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 9,376 | $8.12 | $76,133.12 |
DisclosureSEC source: 0001780660-26-000015 · form4.xml · nonDerivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 290,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,344 | $3.99 | $9,352.56 |
DisclosureSEC source: 0001780660-26-000015 · form4.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,009 | $8.46 | $16,996.14 |
DisclosureSEC source: 0001780660-26-000015 · form4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 5,792 | $12.14 | $70,314.88 |
DisclosureSEC source: 0001780660-26-000015 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 2,344 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780660-26-000013 · form4.xml · derivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,297 Underlying: Common Stock · 2,344 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 22,564 | $15.07 | $340,039.48 |
DisclosureSEC source: 0001780660-26-000013 · form4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,154 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,344 | $3.99 | $9,352.56 |
DisclosureSEC source: 0001780660-26-000013 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 01:02 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 30,593 | $14.08 | $430,749.44 |
DisclosureSEC source: 0001780660-26-000011 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,374 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.81 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 05, 2026 Filed Mar 10, 2026 00:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 38,074 | $15.09 | $574,536.66 |
DisclosureSEC source: 0001780660-26-000007 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,967 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:35 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 44,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001780660-26-000005 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,041 Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,215 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780660-26-000003 · primary_doc.xml · derivative · entry 10 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,641 Underlying: Common Stock · 14,215 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.